
Sanofi has scrapped its regulatory filing plans and late-stage trials for rare bone marrow cancer treatment fedratinib. The reason given …
Aiforia deal to expand access to pathology AI
SMC accepts atogepant for acute migraine treatment in Scotland
New CCO Ogburn joins Cori Clinical

